Study of a Polygenic Risk Score to Predict the Risk of Pancreatic Ductal Adenocarcinoma
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCatholic University of the Sacred Heart
About this trial
This case-control study aims to evaluate the role of a polygenic risk score in predicting the risk of pancreatic ductal adenocarcinoma (PDAC). The study will compare genetic risk profiles between individuals with PDAC and controls without the disease in order to assess whether a polygenic risk score may help identify individuals at higher risk. The findings may contribute to improving risk stratification and supporting future strategies for early identification and prevention of pancreatic cancer.
Eligibility criteria
Qualifiers
Adults aged 18 years and older.
Able and willing to provide informed consent.
For cases: participants with pancreatic ductal adenocarcinoma.
For controls: participants without pancreatic ductal adenocarcinoma.
Disqualifiers
Age younger than 18 years.
Inability to provide informed consent.
Incomplete or unavailable clinical and/or biological data required for the study.
Any condition that, in the judgment of the investigators, makes the participant unsuitable for inclusion
Trial design
Treatments tested in this trial
- Blood sample collection
Treatment groups
1,140 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov